Hyperkalemic cardiac arrest induced by mannitol administration during craniotomy: A case report and review of the literature

Hua Zheng, Xueqin Cao, Feng Gao, Xinhua Li, Li Wan and Ailin Luo*
Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Introduction: Mannitol is the most widely used hyperosmolar agent during neurosurgical procedures. However, its use can lead to serious hyperkalemia with altered cardiac conduction.

Case presentation: Here we report a case in which a 40-min cardiac arrest was caused by mannitol-induced hyperkalemia during craniotomy. In addition, we conducted a literature review through a PubMed (MEDLINE) search of the relevant literature published so far. Details of all cases are presented and discussed. The results suggest that male patients or patients with uncontrolled diabetes might be at higher risk to develop this phenomenon. The results also suggest that the high dose and rapid rate of infusion of mannitol might contribute to mannitol-induced hyperkalemia.

Conclusion: Physicians should be aware of the existence of mannitol-induced hyperkalemia. Although the mechanism of this complication is not well established, it is prudent to administer mannitol cautiously, especially in patients with uncontrolled diabetes. Continuous electrocardiogram monitoring and frequent measurements of serum electrolytes can help to detect and treat possible life-threatening events induced by mannitol-induced hyperkalemia early.

KEYWORDS
mannitol, hyperkalemia, cardiac arrest, craniotomy, complication

Introduction

Mannitol, a sugar alcohol, is used commonly to reduce intracranial pressure and brain bulk in neurosurgical patients (1). Mannitol acts as an osmotic diuretic, increasing blood osmolality acutely, and shifting water from the intracellular and interstitial compartments into the intravascular space, thus reducing brain water content (2). This response decreases brain bulk and thereby the quality of surgical exposure (3). However, mannitol administration can lead to serious electrolyte abnormalities, especially hyperkalemia (4). Here we report a case of life-threatening hyperkalemia induced by mannitol administration during supratentorial brain tumor
resection. In addition, we review the pertinent literature and discuss the prevalence, mechanism, risk factors, diagnosis, and treatment of mannitol-induced hyperkalemia.

Case presentation

A 66-year-old (height: 175 cm, body weight: 72 kg) man presented with left leg weakness for 3 months and dizziness for 1 month. Brain magnetic resonance imaging showed a sphenoid wing meningioma with diffuse brain edema of the right hemisphere and subfalcine hernia. He had a history of type 2 diabetes that was managed using insulin. He smoked half to one pack of cigarettes daily for 45 years and had recently stopped smoking. Previous surgical procedures included lumbar discectomy, phacoemulsification cataract surgery, and partial prostatectomy. His physical examination was notable for left leg weakness. His lungs were clear to auscultation bilaterally on pulmonary examination. He had a normal heart rate and a regular heart rhythm on cardiac examination. Preoperative electrocardiogram and echocardiography were both normal. Preoperative laboratory tests showed a normal complete blood count and comprehensive metabolic panel except for high blood sugar.

The patient was scheduled for a brain tumor resection through the transtemporal approach. When he arrived in the operating room, his initial electrocardiogram showed normal sinus rhythm at 72 beats per minute (bpm) and his blood pressure was 140/88 mmHg. Other vital signs included: respiratory rate, 15 breaths per minute; oxygen saturation using pulse oximetry (SpO2) in room air, 98%; temperature, 37 °C. After preoxygenation and anesthetic induction with sufentanil, cisatracurium, and propofol, endotracheal intubation proceeded uneventfully. Then a right femoral arterial catheter was placed, as well as a left dorsalis pedis arterial catheter. Arterial blood gas and electrolyte analysis was sent and the potassium concentration of 5.9 mmol/L. A repeat sample for arterial blood gas analysis was sent and the potassium concentration was 6.4 mmol/L. The patient rapidly developed ventricular fibrillation followed by asystole. Cardiopulmonary resuscitation (CPR) with chest compressions was initiated immediately. First, 1 mg of epinephrine, 1 g of calcium gluconate, and 10 U of regular insulin were given intravenously. Then 250 ml of 5% sodium bicarbonate was infused. Repetitive attempts at electrical defibrillation were made and the patient intermittently regained normal sinus rhythm. After 40 min of CPR, the patient returned to sustained sinus rhythm while his potassium decreased to 3.8 mmol/L.

After surgery, the patient was conveyed to an intensive care unit. The postoperative evaluation did not show pulmonary embolism, myocardial infarction, or any other cardiovascular abnormalities. The patient was tracheally extubated on postoperative day 1 and transferred to a general ward on postoperative day 3. Two weeks later, the patient was discharged home without neurologic deficits or clinical sequelae.

Literature review

A literature review was conducted through a PubMed (MEDLINE) search of the literature published up to August 1, 2022. “Hyperkalemia” AND “mannitol” were used as search terms. No language and start date restrictions were applied. Further studies were identified by screening the references of publications that covered the topics. Those studies that did not accurately describe the clinical presentation, diagnostic process, and therapeutic procedures were excluded. A total of 11 relevant publications with 14 case reports were included (Table 1).

Discussion

Mannitol has been used to reduce intracranial pressure and volume for 60 years. However, the use of mannitol can cause life-threatening adverse effects. Here, we report a case in which hyperkalemic cardiac arrest caused by infusion of mannitol in a patient with uncontrolled diabetes. Clinical features and treatments of this case are described and discussed in the context of the relevant literature. This case report and literature review indicates the importance of early recognition and rapid correction of mannitol-induced hyperkalemia.

The occurrence of significant hyperkalemia after administration of mannitol was relatively rare but life-threatening. Most of the cases reported in the literature were from Asia, especially Japan. According to preoperative diagnosis, nine (60%) of the patients had cerebrovascular
diseases, and six (40%) had cerebral tumors. The ages of the patients ranged from 15 to 69 years, and the mean age was 48 years. Of the 15 patients, 14 (93%) were male and only 1 (7%) was female. These results suggest that male patients might be at higher risk of lethal mannitol-induced hyperkalemia.

The mechanism of the rise in serum potassium following mannitol is incompletely identified. Some possible mechanisms have been offered to explain this phenomenon. First, hemolysis due to the direct effect of hypertonic mannitol on the red blood cells. However, Evers et al. showed that the survival time of the red blood cells was not adversely affected after the injection of mannitol (16). The results from all published case reports and us also did not suggest hemolysis to account for the increase in potassium. Second, acidosis secondary to dilution of bicarbonate, which is attributed to a temporary intravascular volume expansion after mannitol administration. Third, physiological response to a rise of H⁺ concentration. According to the strong ion difference theory, hypertonic mannitol decreases sodium reabsorption and the strong ion difference with a resultant increase in H₂O dissociation and H⁺ concentration (17). However, in a retrospective study by Hirotta et al., no correlation between mannitol-induced hyperkalemia and acid-base abnormalities was detected (6). Previous case reports and ours also did not support the second and third proposed mechanisms.

Another mechanism of mannitol-induced hyperkalemia that has been considered is a solvent drag. According to this theory, increased intracellular osmolality and intracellular water loss result in the movement of water out of cells and the shift of potassium along with it. In the current report, impaired function of glucoregulatory hormones may also play an important role in mannitol-induced hyperkalemia. Under normal circumstances, increased serum potassium stimulates insulin release which then puts potassium into the cells (18). But this response is impaired in uncontrolled diabetes mellitus. In addition, marked hyperglycemia also accounts for hyperkalemia. Thus, in patients with uncontrolled diabetes mellitus, abandonment of or caution with the use of mannitol is recommended.

It is reported that mannitol-induced hyperkalemia is dose-dependent (19). The doses of mannitol used in the current literature review vary from 0.6 to 1.5 g/kg. However, a systematic study indicated that an equivalent intracranial pressure reduction can be achieved with 0.25 g/kg of mannitol while avoiding the risk of severe adverse effects (20). In addition, the rapid rate of infusion of mannitol may also contribute to mannitol-induced hyperkalemia. Most patients presented in Table 1 received mannitol within 20 min, even though a high dose of up to 80 g of mannitol was

![Timeline of surgery and results of arterial blood gas analysis of the patient.](FIGURE 1)
| Reference | Characteristics of patients | Infusion of mannitol | Electrocardiogram changes | Potassium concentration (mmol/L) | Treatment |
|-----------|-----------------------------|----------------------|---------------------------|---------------------------------|-----------|
|           | Age (years) | Sex | Diagnosis | Dose g (g/kg) | Duration (minutes) | Onset time<sup>a</sup> (minutes) | Manifestations | Baseline | Peak | End of surgery |
| 1 (5)     | 52 | M | Artery aneurysm | 60 (1.0) | 20 | 60 | Peaked T waves, widened QRS, VT | 4.8 | 6.8 | 5.0 | Insulin with glucose, lidocaine, calcium |
| 2 (6)     | Patient 1 | 34 | M | Artery aneurysm | 60 (1.0) | 20 | 30 | Peaked T waves | 3.1 | 5.4 | 3.5 | Hyperventilation, calcium, insulin with glucose |
| Patient 2 | 68 | M | Intracerebral hemorrhage | 100 (1.3) | 45 | 90 | Peaked T waves, bigeminy | 4.1 | 6.1 | 5.4 | Lidocaine, bicarbonate, hyperventilation |
| 3 (7)     | 15 | M | Arteriovenous malformation | 60 (1.1) | NA | 45 | Peaked T waves, widened QRS | 5.3 | 6.7 | 5.2 | Calcium, bicarbonate |
| 4 (8)     | 31 | F | Astrocytoma | 80 (1.0) | 45 | 60 | Peaked T waves | 4.1 | 6.1 | 4.5 | Calcium, insulin with dextrose |
| 5 (9)     | 41 | M | Cerebral aneurysm | 120 (NA) | 40 | 40 | Peaked T waves, widened QRS, VT, VF, asystole | 4.1 | 6.1 | 3.9 | Calcium, bicarbonate, insulin with dextrose |
| 6 (10)    | 43 | M | Cerebellar tumor | 60 (NA) | NA | 30 | NA | 4.8 | 6.7 | 4.0 | NA |
| 7 (11)    | 23 | M | Cerebellar hemangioblastoma | NA (1.5) | 20 | 30 | Peaked T waves, widened QRS | 4.8 | 9.0 | 4.1 | Calcium, insulin with dextrose, furosemide |
| 8 (12)    | Patient 1 | 57 | M | Artery aneurysm | 45 (0.7) | 15 | 125 | Peaked T waves | 4.0 | 6.0 | 4.4 | Furosemide, bicarbonate |
| Patient 2 | 49 | M | Artery aneurysm | 30 (NA) | 20 | 170 | Peaked T waves | 3.7 | 5.7 | 5.0 | Furosemide, bicarbonate |
| 9 (13)    | 43 | M | Metastatic tumor | 80 (0.7) | 20 | 80 | Peaked T waves, widened QRS, VT, VF, asystole | 4.2 | 6.5 | 6.1 | None |
| 10 (14)   | 62 | M | Artery aneurysm | 40 (0.6) | 60 | 80 | VT, peaked T waves | 4.1 | 6.4 | 3.5 | Calcium, furosemide, insulin with glucose |
|           | 11 (15) | Patient 1 | 69 | M | Cerebellar tumor | 50 (0.8) | NA | 25<sup>b</sup> | VF, asystole | 4.2 | 6.0 | 5.8 | Bicarbonate |
| Patient 2 | 69 | M | Artery aneurysm | 50 (0.6) | NA | None | None | 4.4 | 6.4 | 5.1 | Insulin |
| Current report | 66 | M | Sphenoid wing meningioma | 50 (0.7) | 20 | 50 | Peaked T waves, VF, asystole | 3.9 | 6.6 | 3.6 | Calcium, insulin, bicarbonate |

<sup>a</sup>Time between the start of mannitol infusion and onset of electrocardiogram changes.
<sup>b</sup>Time between completion of mannitol infusion and onset of electrocardiogram changes.
F, female; M, male; NA, not available; VF, ventricular fibrillation; VT, ventricular tachycardia.
administered. The dose and rate of infusion of mannitol as risk factors were also confirmed in the current report, as the patient had received preoperatively 0.3 g/kg mannitol over 30 min without any adverse effect in general ward. Collectively, high doses and rapid rates of infusion of mannitol should be avoided during craniotomy. In patients with contraindications of mannitol, hypertonic saline might be used as an alternative (21).

The changes in electrocardiogram, such as peaked T waves and widened QRS, were usually the first finding of mannitol-induced hyperkalemia. However, these changes did not occur in every case and developed quickly to lethal arrhythmia. In addition, the time between the start of mannitol infusion and the onset of electrocardiogram changes ranged from 30 to 170 min. Thus, mannitol should be administered with continuous electrocardiogram monitoring and repeated arterial blood gas analysis throughout the surgical procedures. When mannitol-induced hyperkalemia occurs, it is a medical emergency that requires rapid treatment. Based on the onset time and mechanisms, Calcium, insulin, and bicarbonate were the first choices to treat mannitol-induced hyperkalemia.

Conclusion

Hyperkalemia is a rare but life-threatening complication of mannitol administration during craniotomy. This phenomenon is more likely to occur in male patients. Although its underline mechanisms remain unknown, high doses and rapid rates of infusion of mannitol may serve as risk factors. Continuous electrocardiogram monitoring and repeated arterial blood gas analysis are essential after mannitol administration. When mannitol-induced hyperkalemia occurs, early recognition and rapid correction of hyperkalemia may prevent harmful events.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

References

1. Ropper AH. Hyperosmolar therapy for raised intracranial pressure. N Engl J Med. (2012) 367(8):746-52. doi: 10.1056/NEJMct1206321
2. Freeman N, Welbourne J. Osmotherapy: science and evidence-based practice. BJA Educ. (2018) 18(9):284-90. doi: 10.1016/j.bjao.2018.05.005
3. Bruder N, Ravussin P. Chapter 11—Supratentorial masses: Anesthetic considerations. In: JE Cottrell, WL Young, editors. Cottrell and Young’s Neuroanesthesia. 5th ed. Philadelphia, PA: Mosby (2010). p. 184–202.
4. Ben Salem C, Badreddine A, Fatallah N, Slim R, Himouda H. Drug-induced hyperkalemia. Drug Saf. (2014) 37(9):677-92. doi: 10.1007/s40264-014-0196-1
5. Seto A, Murakami M, Fukuyama H, Niuji K, Aoyama K, Takenaka I, et al. Ventricular tachycardia caused by hyperkalemia after administration of hypertonic mannitol. Anesthesiology. (2000) 93(5):1359-61. doi: 10.1097/00000542-200011000-00036
6. Hirota K, Hara T, Hosoi S, Sasaki Y, Hara Y, Adachi T. Two cases of hyperkalemia after administration of hypertonic mannitol during craniotomy. J Anesth. (2005) 19(1):75-7. doi: 10.1007/s00540-004-0270-4
7. Kimura S, Ogawa H, Katayama Y. Hyperkalemia caused by intravenous administration of mannitol in a patient with arteriovenous malformation: case report. No Shinkei Geka. (2006) 34(1):51-6. PMID: 16440697

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of Tongji Hospital, Tongji Medical College, and Huazhong University of Science and Technology. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HZ, FG, and AL contributed to the study design. HZ collected the data, performed the analysis, and wrote the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors thank the patient for providing informed consent.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
8. Hassan ZU, Kruer JJ, Fuhrman TM. Electrolyte changes during craniotomy caused by administration of hypertonic mannitol. *J Clin Anesth*. (2007) 19(4):307–9. doi: 10.1016/j.jclinane.2006.09.005

9. Flynn BC. Hyperkalemic cardiac arrest with hypertonic mannitol infusion: the strong ion difference revisited. *Anesth Analg*. (2007) 104(1):225–6. doi: 10.1213/01.ane.0000249801.01029.55

10. Tobita K, Kohno T. Case of hyperkalemia after the administration of hypertonic mannitol during craniotomy. *Masui*. (2010) 59(5):641–4. PMID: 20486581

11. Sharma J, Salhotra R. Mannitol-induced intraoperative hyperkalemia, a little-known clinical entity. *J Anaesthesiol Clin Pharmacol*. (2012) 28(4):546–7. doi: 10.4103/0970-9185.101965

12. Nakasuji M, Nomura M, Yoshioka M, Miyata T, Imanaka N, Tanaka M. Hypertonic mannitol-induced hyperkalemia during craniotomy. *J Anesth Clinic Res*. (2013) 4(3):299. doi: 10.4172/2155-6148.1000299

13. Fanous AA, Tick RC, Gu EY, Fenstermaker RA. Life-threatening mannitol-induced hyperkalemia in neurosurgical patients. *World Neurosurg*. (2016) 91:672.e5–672.e9. doi: 10.1016/j.wneu.2016.04.021

14. Gohara A, Okamatsu-Kifuji S, Shono S, Higashi M, Yamaura K. Ventricular tachycardia without preceding electrocardiogram change after hypertonic mannitol administration: a case report. *JA Clin Rep*. (2018) 4(1):54. doi: 10.1186/s40981-018-0191-0

15. Chen H-i, Zhu B, Yao L. Hyperkalemia after administration of hypertonic mannitol: two case reports. *Transl Perioper Pain Med*. (2018) 5(4):101–4. doi: 10.31480/2330-4871/078

16. Evers W, Race GB, Bell EG. Red blood cell survival after mannitol infusion: a clinical study in human volunteers using Cr 51. *Can Anaesth Soc J*. (1971) 18(6):631–6. doi: 10.1007/BF03026183

17. Stewart PA. Modern quantitative acid-base chemistry. *Can J Physiol Pharmacol*. (1983) 61(12):1444–61. doi: 10.1139/y83-207

18. Cox M, Sterns RH, Singer I. The defense against hyperkalemia: the roles of insulin and aldosterone. *N Engl J Med*. (1978) 299(10):525–32. doi: 10.1056/NEJM197809072991007

19. Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. *Can J Anaesth*. (1987) 34(5):442–6. doi: 10.1007/BF03014345

20. Marshall LF, Smith RW, Rauscher LA, Shapiro HM. Mannitol dose requirements in brain-injured patients. *J Neurosurg*. (1978) 48(2):169–72. doi: 10.3171/jns.1978.48.2.0169

21. Hernandez-Palazon J, Fuentes-Garcia D, Domenech-Asensi P, Piqueras-Perez C, Falcon-Arana L, Burguillos-Lopez S. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol for brain relaxation during elective supratentorial craniotomy. *Br J Neurosurg*. (2016) 30(1):70–5. doi: 10.3109/02688697.2015.1109061